Physician profile
Dana E Rockwell
NPI 1912261686
$15,707.78
in general payments reported to CMS, 2019-2025
27 companies · $5,696 in 2025
The $5,696 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $706 · 2021: $1,204 · 2022: $1,413 · 2023: $3,780 · 2024: $1,944 · 2025: $5,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,396 · Consulting Fee: $3,540 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,396.23 |
| Consulting Fee | $3,540.00 |
| Education | $483.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,343.60 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $2,539.79 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Abbvie INC. | $1,794.81 | 2019-2025 | |
| Horizon Therapeutics Plc | $994.38 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $798.07 | 2019-2025 | |
| Pfizer INC. | $449.81 | 2019-2025 | |
| Genzyme Corporation | $409.36 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $382.58 | 2019-2025 | Orencia |
| Lilly USA, LLC | $374.16 | 2019-2024 | Taltz |
| Ucb, INC. | $363.37 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $312.53 | 2021-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $295.24 | 2019-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $165.14 | 2022-2023 | Tremfya |
| Genentech USA, INC. | $78.14 | 2021-2025 | Gazyva, Actemra |
| Aurinia Pharma U.S., INC. | $67.64 | 2025 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $52.00 | 2025 | Jubbonti |
| Pacira Therapeutics, INC. | $49.55 | 2019 | |
| Organon LLC | $48.51 | 2024-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.03 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $24.64 | 2025 | |
| Alexion Pharmaceuticals, INC. | $20.07 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.76 | 2022 | |
| Antares Pharma, INC. | $16.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.85 | 2019 | |
| Merck Sharp & Dohme LLC | $15.53 | 2020 | |
| Hikma Pharmaceuticals USA | $14.12 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Rockwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.